Are phosphodiesterase 4 inhibitors just more theophylline?

DOI: 10.1016/j.jaci.2006.02.045
Journal of Allergy and Clinical Immunology, 2006, 117, 1237-4

#	Paper	IF	Citations
94	The effective treatment of COPD: Anticholinergics and what else?. *Drug Discovery Today: Therapeutic Strategies*, **2006**, 3, 277-286		12
93	Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. *Expert Opinion on Therapeutic Targets*, **2007**, 11, 1273-86	6.4	22
92	Airway Remodeling: Effect of Current and Future Asthma Therapies. *Current Respiratory Medicine Reviews*, **2007**, 3, 297-308	0.3	
91	Bibliography. Current world literature. Obstructive, occupational and environmental diseases. *Current Opinion in Pulmonary Medicine*, **2007**, 13, 142-55	3	
90	The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. *Respiratory Medicine*, **2007**, 101, 957-62	4.6	24
89	Summing up 100 years of asthma. *Respiratory Medicine*, **2007**, 101, 378-88	4.6	47
88	Treating systemic effects of COPD. *Trends in Pharmacological Sciences*, **2007**, 28, 544-50	13.2	25
87	Novel 8-heterocyclyl xanthine derivatives in drug development - an update. *Expert Opinion on Drug Discovery*, **2007**, 2, 1161-83	6.2	12
86	PDE4 inhibitors: current status. *British Journal of Pharmacology*, **2008**, 155, 308-15	8.6	248
85	Treatment strategies for allergy and asthma. *Nature Reviews Immunology*, **2008**, 8, 218-30	36.5	457
84	Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment. *British Journal of Clinical Pharmacology*, **2008**, 65, 803-10	3.8	19
83	The rabbit as a model to study asthma and other lung diseases. *Pulmonary Pharmacology and Therapeutics*, **2008**, 21, 721-30	3.5	31
82	Roflumilast: systemic therapy for chronic obstructive pulmonary disease. *Expert Review of Respiratory Medicine*, **2008**, 2, 539-49	3.8	6
81	Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma. *Expert Opinion on Investigational Drugs*, **2008**, 17, 811-8	5.9	29
80	Chronic Obstructive Pulmonary Disease Exacerbations. **2008**,		2
79	Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design. *Current Pharmaceutical Design*, **2008**, 14, 3854-72	3.3	49
78	NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase 3 inhibitor, suppress the asthmatic response in guinea pigs, with both bronchodilating and anti-inflammatory effects. *European Journal of Pharmacology*, **2009**, 618, 63-9	5.3	6

77	Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes. *American Journal of Physiology - Renal Physiology*, **2009**, 297, G1077-84	5.1	10
76	PDE4 inhibitors - a review of the current field. *Progress in Medicinal Chemistry*, **2009**, 47, 37-74	7.3	50
75	Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. *Lancet, The*, **2009**, 374, 695-703	40	469
74	Current and Emerging Therapies in Chronic Obstructive Pulmonary Disease. **2010**, 747-790		
73	The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. *Respiratory Research*, **2010**, 11, 26	7.3	72
72	Montelukast: more than a cysteinyl leukotriene receptor antagonist?. *Scientific World Journal, The*, **2010**, 10, 2403-13	2.2	66
71	The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease. *Therapeutic Advances in Respiratory Disease*, **2010**, 4, 195-8	4.9	5
70	Evaluation of the effect of phosphodiesterase on equine platelet activation and the effect of antigen challenge on platelet phosphodiesterase activity in horses with recurrent airway obstruction. *American Journal of Veterinary Research*, **2010**, 71, 534-40	1.1	7
69	Phosphodiesterase type 4 (PDE4) inhibition: The search for effective therapy with minimal side effects. *Progress in Respiratory Research*, **2010**, 269-278		2
68	The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. *Pulmonary Pharmacology and Therapeutics* , **2010**, 23, 235-56	3.5	220
67	Doxofylline: a "novofylline". *Pulmonary Pharmacology and Therapeutics*, **2010**, 23, 231-4	3.5	36
66	Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. *Expert Opinion on Pharmacotherapy*, **2010**, 11, 441-9	4	18
65	Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. *Handbook of Experimental Pharmacology*, **2011**, 85-119	3.2	31
64	Phosphodiesterases as Drug Targets. *Handbook of Experimental Pharmacology*, **2011**,	3.2	20
63	Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. *Trends in Pharmacological Sciences*, **2011**, 32, 495-506	13.2	74
62	Development of an in vitro liver toxicity prediction model based on longer term primary rat hepatocyte culture. *Toxicology Letters*, **2011**, 206, 189-96	4.4	25
61	Synergic bronchodilator effects of a phosphodiesterase 3 inhibitor olprinone with a volatile anaesthetic sevoflurane in ovalbumin-sensitised guinea pigs. *European Journal of Anaesthesiology*, **2011**, 28, 519-24	2.3	3
60	Virtual high throughput screening in new lead identification. *Combinatorial Chemistry and High Throughput Screening*, **2011**, 14, 840-60	1.3	47

59	Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. *British Journal of Pharmacology*, **2011**, 163, 53-67	8.6	161
58	A new method based on electrospray ionisation ion mobility spectrometry (ESI-IMS) for simultaneous determination of caffeine and theophylline. *Food Chemistry*, **2011**, 126, 1964-70	8.5	78
57	Development of new drugs for the treatment of respiratory diseases: from concept to the clinic. *Journal of Drug Delivery Science and Technology*, **2011**, 21, 347-352	4.5	2
56	Emerging anti-inflammatory strategies for COPD. *European Respiratory Journal*, **2012**, 40, 724-41	13.6	68
55	Indomethacin-induced small intestinal injury is ameliorated by cilostazol, a specific PDE-3 inhibitor. *Scandinavian Journal of Gastroenterology*, **2012**, 47, 993-1002	2.4	14
54	The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism. *Pulmonary Pharmacology and Therapeutics*, **2012**, 25, 55-61	3.5	35
53	High sensitive determination of theophylline based on gold nanoparticles/l-cysteine/Graphene/Nafion modified electrode. *Electrochimica Acta*, **2012**, 78, 434-439	6.7	29
52	Bifunctional Compounds for the Treatment of COPD. *Annual Reports in Medicinal Chemistry*, **2012**, 209-22	2.6	6
51	Emerging drugs for chronic obstructive pulmonary disease. *Expert Opinion on Emerging Drugs*, **2012**, 17, 61-82	3.7	20
50	PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. *Clinical Pharmacology and Therapeutics*, **2012**, 91, 134-42	6.1	58
49	Pharmacology and therapeutics of bronchodilators. *Pharmacological Reviews*, **2012**, 64, 450-504	22.5	311
48	Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. *Dermatology and Therapy*, **2013**, 3, 1-15	4	80
47	Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. *Journal of Pharmacology and Experimental Therapeutics*, **2013**, 346, 414-23	4.7	67
46	Discovery of New Medicines. **2013**, 1-31		
45	Curine inhibits eosinophil activation and airway hyper-responsiveness in a mouse model of allergic asthma. *Toxicology and Applied Pharmacology*, **2013**, 273, 19-26	4.6	18
44	Synergistic effects of polyphenols and methylxanthines with Leucine on AMPK/Sirtuin-mediated metabolism in muscle cells and adipocytes. *PLoS ONE*, **2014**, 9, e89166	3.7	57
43	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. *BMC Pulmonary Medicine*, **2014**, 14, 166	3.5	15
42	Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?. *Drugs*, **2014**, 74, 1983-92	12.1	23

41	PDE4: Recent Medicinal Chemistry Strategies to Mitigate Adverse Effects. *Methods and Principles in Medicinal Chemistry*, **2014**, 45-64	0.4	2
40	Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. *European Respiratory Journal*, **2014**, 44, 475-82	13.6	37
39	Graphene layer modified glassy carbon electrode for the determination of norepinephrine and theophylline in pharmaceutical formulations. *Analytical Methods*, **2014**, 6, 2181	3.2	26
38	Bronchodilators: current and future. *Clinics in Chest Medicine*, **2014**, 35, 191-201	5.3	54
37	Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. *Pulmonary Pharmacology and Therapeutics*, **2015**, 32, 15-23	3.5	37
36	High sensitive determination of theophylline based on manganese oxide nanoparticles/multiwalled carbon nanotube nanocomposite modified electrode. *Ionics*, **2015**, 21, 1121-1128	2.7	16
35	Absorption, distribution, metabolism and excretion of novel phosphodiesterase type 4 inhibitor ASP3258 in rats. *Biopharmaceutics and Drug Disposition*, **2015**, 36, 34-48	1.7	1
34	MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis. *Expert Opinion on Biological Therapy*, **2016**, 16, 1435-1441	5.4	1
33	Xanthines and Phosphodiesterase Inhibitors. *Handbook of Experimental Pharmacology*, **2017**, 237, 63-91	3.2	30
32	Bifunctional Drugs for the Treatment of Respiratory Diseases. *Handbook of Experimental Pharmacology*, **2017**, 237, 197-212	3.2	14
31	Application of a Physiologically Based Pharmacokinetic Model to Study Theophylline Metabolism and Its Interactions With Ciprofloxacin and Caffeine. *CPT: Pharmacometrics and Systems Pharmacology*, **2016**, 5, 74-81	4.5	3
30	Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. *Journal of Thoracic Disease*, **2017**, 9, 1144-1154	2.6	29
29	Interaction between saliva's adenosine and tick parasitism: effects on feeding and reproduction. *Parasites and Vectors*, **2017**, 10, 326	4	1
28	JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease. *Annals of Allergy, Asthma and Immunology*, **2018**, 120, 367-375	3.2	35
27	Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. *Pharmaceutical Patent Analyst*, **2018**, 7, 249-257	0.6	6
26	Development of a measure to assess factors associated with college students Willingness and Readiness to Act in a Food Allergic Emergency (WilRAFAE): A pilot. *Cogent Psychology*, **2018**, 5, 1549006	1	
25	Xanthine scaffold: scope and potential in drug development. *Heliyon*, **2018**, 4, e00829	3.6	41
24	Bronchodilator Therapy for Asthma. **2018**, 1-31		

23	Phosphodiesterase 3 and 4 Inhibition: Facing a Bright Future in Asthma Control. **2018**,		4
22	Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. *International Journal of COPD*, **2018**, 13, 813-822	3	17
21	Stimulatory Effects of KPR-A148 on Osteoblast Differentiation and Bone Regeneration. *Tissue Engineering and Regenerative Medicine*, **2019**, 16, 405-413	4.5	5
20	Experimental and investigational phosphodiesterase inhibitors in development for asthma. *Expert Opinion on Investigational Drugs*, **2019**, 28, 261-266	5.9	5
19	Bronchodilator Therapy for Asthma. **2019**, 841-871		
18	Immunological considerations in the development of vaccines. *Human Vaccines and Immunotherapeutics*, **2020**, 16, 412-418	4.4	9
17	Screening for drugs to reduce zebrafish aggression identifies caffeine and sildenafil. *European Neuropsychopharmacology*, **2020**, 30, 17-29	1.2	8
16	Combinatorial library generation, molecular docking and molecular dynamics simulations for enhancing the isoflavone scaffold in phosphodiesterase inhibition. *New Journal of Chemistry*, **2020**, 44, 19472-19488	3.6	3
15	New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19. *European Journal of Pharmacology*, **2020**, 889, 173615	5.3	6
14	Advances in the Development of Phosphodiesterase-4 Inhibitors. *Journal of Medicinal Chemistry*, **2020**, 63, 10594-10617	8.3	24
13	Bromine Radical Catalysis by Energy Transfer Photosensitization. *ACS Catalysis*, **2020**, 10, 2609-2614	13.1	19
12	New Avenues for Phosphodiesterase Inhibitors in Asthma. *Journal of Experimental Pharmacology*, **2021**, 13, 291-302	3	4
11	Current and Emerging Therapies in Chronic Obstructive Pulmonary Disease. 1-47		
10	Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases. *Frontiers in Pharmacology*, **2021**, 12, 518345	5.6	1
9	Curine inhibits eosinophil activation and airway hyper-responsiveness in a mouse model of allergic asthma. *Toxicology and Applied Pharmacology*, **2013**, 273, 19-26	4.6	17
8	A pathophysiological role of PDE3 in allergic airway inflammation. *JCI Insight*, **2018**, 3,	9.9	23
7	Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats. *PLoS ONE*, **2008**, 3, e3445	3.7	16
6	Ro 20-1724 Ameliorates Learning Deficit and Long-Term Memory Impairment Secondary to Repeated Ketamine Anesthesia in Young Rats. *Neuroscience and Medicine*, **2013**, 04, 155-160	0.3	1

5	Phosphodiesterase-4 Inhibitors and Theophylline. **2008**, 273-279		
4	Treating COPD with PDE 4 inhibitors. *International Journal of COPD*, **2007**, 2, 517-33	3	18
3	Ligustrazine Inhibits Lung Phosphodiesterase Activity in a Rat Model of Allergic Asthma.. *Computational and Mathematical Methods in Medicine*, **2022**, 2022, 1452116	2.8	
2	.. *Journal of Pharmacology and Experimental Therapeutics*, **2022**,	4.7	1
1	cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features. **2023**, 34, 101438		0